Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  10/2/2012
Clinical Research Facility
mi
from
Phoenix, AZ
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 10/2/2012
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  10/2/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 10/2/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  10/2/2012
Clinical Research Facility
mi
from
Chattanooga, TN
A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 10/2/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas
A Phase I Study of Rindopepimut After Conventional Radiation in Children With Diffuse Intrinsic Pontine Gliomas
Status: Enrolling
Updated:  10/3/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas
A Phase I Study of Rindopepimut After Conventional Radiation in Children With Diffuse Intrinsic Pontine Gliomas
Status: Enrolling
Updated: 10/3/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies
A Multicenter, Open-label, Dose-escalation, Phase I Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Status: Enrolling
Updated:  10/4/2012
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies
A Multicenter, Open-label, Dose-escalation, Phase I Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Status: Enrolling
Updated: 10/4/2012
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies
A Multicenter, Open-label, Dose-escalation, Phase I Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Status: Enrolling
Updated:  10/4/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies
A Multicenter, Open-label, Dose-escalation, Phase I Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
Status: Enrolling
Updated: 10/4/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand
Phase II, Prospective, Non-Randomized Trial Investigating the Intra-Operative Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand
Status: Enrolling
Updated:  10/4/2012
Mayo Clinic Rochester
mi
from
Rochester, MN
Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand
Phase II, Prospective, Non-Randomized Trial Investigating the Intra-Operative Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand
Status: Enrolling
Updated: 10/4/2012
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Post-transplant Cyclophosphamide and Sirolimus Following RIC Transplant
A Phase II Trial of Post-Transplant Cyclophosphamide and Sirolimus for Graft-versus-host Disease (GVHD) Prophylaxis Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated:  10/8/2012
Northside Hospital
mi
from
Atlanta, GA
Post-transplant Cyclophosphamide and Sirolimus Following RIC Transplant
A Phase II Trial of Post-Transplant Cyclophosphamide and Sirolimus for Graft-versus-host Disease (GVHD) Prophylaxis Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated: 10/8/2012
Northside Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors
A Phase I Trial of Panobinostat (LBH589) and Epirubicin in Patients With Solid Tumor Malignancies
Status: Enrolling
Updated:  10/10/2012
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors
A Phase I Trial of Panobinostat (LBH589) and Epirubicin in Patients With Solid Tumor Malignancies
Status: Enrolling
Updated: 10/10/2012
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors
A Phase 1 Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors
Status: Enrolling
Updated:  10/10/2012
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors
A Phase 1 Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors
Status: Enrolling
Updated: 10/10/2012
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors
A Phase 1 Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors
Status: Enrolling
Updated:  10/10/2012
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors
A Phase 1 Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors
Status: Enrolling
Updated: 10/10/2012
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab
Status: Enrolling
Updated:  10/10/2012
University of California, San Francisco
mi
from
San Francisco, CA
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab
Status: Enrolling
Updated: 10/10/2012
University of California, San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  10/12/2012
Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 10/12/2012
Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  10/12/2012
The Karmanos Cancer Institute
mi
from
Detriot, MI
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 10/12/2012
The Karmanos Cancer Institute
mi
from
Detriot, MI
Click here to add this to my saved trials
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  10/12/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 10/12/2012
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated:  10/12/2012
University of Wisconsin Madison, Carbone Cancer Center
mi
from
Madison, WI
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)
Status: Enrolling
Updated: 10/12/2012
University of Wisconsin Madison, Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence
Status: Enrolling
Updated:  10/12/2012
University of Kansas Medical Center Cancer Center
mi
from
Kansas City, KA
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence
Status: Enrolling
Updated: 10/12/2012
University of Kansas Medical Center Cancer Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Aloxi for Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma (MG) Patients Receiving Irinotecan With Bevacizumab
A Phase II Single Arm Trial of Palonesetron (PALO) for the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma Patients Receiving Irinotecan in Combination With Bevacizumab
Status: Enrolling
Updated:  10/15/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Aloxi for Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma (MG) Patients Receiving Irinotecan With Bevacizumab
A Phase II Single Arm Trial of Palonesetron (PALO) for the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma Patients Receiving Irinotecan in Combination With Bevacizumab
Status: Enrolling
Updated: 10/15/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated:  10/15/2012
Cedars Sinai Medical Center Outpatient Cancer Ctr. (3)
mi
from
Los Angeles, CA
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated: 10/15/2012
Cedars Sinai Medical Center Outpatient Cancer Ctr. (3)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated:  10/15/2012
Dana Farber Cancer Institute SC-2
mi
from
Boston, MA
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated: 10/15/2012
Dana Farber Cancer Institute SC-2
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated:  10/15/2012
Montefiore Medical Center MMC
mi
from
Bronx, NY
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated: 10/15/2012
Montefiore Medical Center MMC
mi
from
Bronx, NY
Click here to add this to my saved trials
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated:  10/15/2012
Carolina's Medical Center - Mecklenburg Medical Group Blumenthal Cancer Center
mi
from
Charlotte, NC
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated: 10/15/2012
Carolina's Medical Center - Mecklenburg Medical Group Blumenthal Cancer Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated:  10/15/2012
Oregon Health and Science University Knight Cancer Institute
mi
from
Portland, OR
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated: 10/15/2012
Oregon Health and Science University Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated:  10/15/2012
Fox Chase Cancer Center FCC
mi
from
Philadelphia, PA
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated: 10/15/2012
Fox Chase Cancer Center FCC
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated:  10/15/2012
MD Anderson Cancer Center/University of Texas UT MD Anderson Cancer Ctr
mi
from
Houston, TX
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
Status: Enrolling
Updated: 10/15/2012
MD Anderson Cancer Center/University of Texas UT MD Anderson Cancer Ctr
mi
from
Houston, TX
Click here to add this to my saved trials
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
An Open-label, Single-arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination With Trastuzumab Standard Therapy as Second-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
Status: Enrolling
Updated:  10/15/2012
UCLA/ University of California Los Angeles UCLA LeConte Location
mi
from
Los Angeles, CA
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
An Open-label, Single-arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination With Trastuzumab Standard Therapy as Second-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
Status: Enrolling
Updated: 10/15/2012
UCLA/ University of California Los Angeles UCLA LeConte Location
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
An Open-label, Single-arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination With Trastuzumab Standard Therapy as Second-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
Status: Enrolling
Updated:  10/15/2012
Clinical Research Alliance, Inc.
mi
from
Lake Success, NY
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
An Open-label, Single-arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination With Trastuzumab Standard Therapy as Second-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
Status: Enrolling
Updated: 10/15/2012
Clinical Research Alliance, Inc.
mi
from
Lake Success, NY
Click here to add this to my saved trials
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
An Open-label, Single-arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination With Trastuzumab Standard Therapy as Second-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
Status: Enrolling
Updated:  10/15/2012
MD Anderson Cancer Center/University of Texas UT SC
mi
from
Houston, TX
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
An Open-label, Single-arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination With Trastuzumab Standard Therapy as Second-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
Status: Enrolling
Updated: 10/15/2012
MD Anderson Cancer Center/University of Texas UT SC
mi
from
Houston, TX
Click here to add this to my saved trials
Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors
Phase Ib Study of Dovitinib in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Plus Carboplatin in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  10/15/2012
Mount Sinai Hospital
mi
from
New York, NY
Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors
Phase Ib Study of Dovitinib in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Plus Carboplatin in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 10/15/2012
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Computerized Intervention for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors
Computerized Intervention for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors
Status: Enrolling
Updated:  10/16/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Computerized Intervention for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors
Computerized Intervention for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors
Status: Enrolling
Updated: 10/16/2012
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV
Predictive Modeling of Anal Dysplasia Progression in HIV
Status: Enrolling
Updated:  10/16/2012
Cincinnati VA Medical Center
mi
from
Cincinnati, OH
Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV
Predictive Modeling of Anal Dysplasia Progression in HIV
Status: Enrolling
Updated: 10/16/2012
Cincinnati VA Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV
Predictive Modeling of Anal Dysplasia Progression in HIV
Status: Enrolling
Updated:  10/16/2012
University of Cincinnati
mi
from
Cincinnati, OH
Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV
Predictive Modeling of Anal Dysplasia Progression in HIV
Status: Enrolling
Updated: 10/16/2012
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Pilot Study of Docosahexaenoic Acid (DHA) in Obese Menopausal Women
Docosahexaenoic Acid (DHA) Reduces Inflammation and Aromatase Expression in Subcutaneous Fat and Inflammation in the Rectosigmoid Mucosa in Obese Postmenopausal Women: A Pilot Study
Status: Enrolling
Updated:  10/17/2012
Rockefeller University
mi
from
New York, NY
A Pilot Study of Docosahexaenoic Acid (DHA) in Obese Menopausal Women
Docosahexaenoic Acid (DHA) Reduces Inflammation and Aromatase Expression in Subcutaneous Fat and Inflammation in the Rectosigmoid Mucosa in Obese Postmenopausal Women: A Pilot Study
Status: Enrolling
Updated: 10/17/2012
Rockefeller University
mi
from
New York, NY
Click here to add this to my saved trials
Open Label Extension In Cancer Patients
Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases
Status: Enrolling
Updated:  10/22/2012
Pfizer Investigational Site
mi
from
Los Angeles, CA
Open Label Extension In Cancer Patients
Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases
Status: Enrolling
Updated: 10/22/2012
Pfizer Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Open Label Extension In Cancer Patients
Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases
Status: Enrolling
Updated:  10/22/2012
Pfizer Investigational Site
mi
from
Bossier City, LA
Open Label Extension In Cancer Patients
Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases
Status: Enrolling
Updated: 10/22/2012
Pfizer Investigational Site
mi
from
Bossier City, LA
Click here to add this to my saved trials
Open Label Extension In Cancer Patients
Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases
Status: Enrolling
Updated:  10/22/2012
Pfizer Investigational Site
mi
from
West Jordan, UT
Open Label Extension In Cancer Patients
Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases
Status: Enrolling
Updated: 10/22/2012
Pfizer Investigational Site
mi
from
West Jordan, UT
Click here to add this to my saved trials
Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
Phase 1 Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 as a Single Agent in Patients With Refractory Solid Tumors
Status: Enrolling
Updated:  10/22/2012
Florida Cancer Specialists
mi
from
Fort Myers, FL
Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
Phase 1 Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 as a Single Agent in Patients With Refractory Solid Tumors
Status: Enrolling
Updated: 10/22/2012
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
Phase 1 Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 as a Single Agent in Patients With Refractory Solid Tumors
Status: Enrolling
Updated:  10/22/2012
University of Oklahoma
mi
from
Oklahoma City, OK
Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
Phase 1 Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 as a Single Agent in Patients With Refractory Solid Tumors
Status: Enrolling
Updated: 10/22/2012
University of Oklahoma
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
Phase 1 Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 as a Single Agent in Patients With Refractory Solid Tumors
Status: Enrolling
Updated:  10/22/2012
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
Phase 1 Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 as a Single Agent in Patients With Refractory Solid Tumors
Status: Enrolling
Updated: 10/22/2012
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study to Test Lung Function After Radiation Therapy
Quantifying Radiation Induced Changes in Pulmonary Function in Irradiated and Non-irradiated Lung Tissue
Status: Enrolling
Updated:  10/23/2012
University of Iowa Department of Radiation Oncology
mi
from
Iowa City, IA
A Study to Test Lung Function After Radiation Therapy
Quantifying Radiation Induced Changes in Pulmonary Function in Irradiated and Non-irradiated Lung Tissue
Status: Enrolling
Updated: 10/23/2012
University of Iowa Department of Radiation Oncology
mi
from
Iowa City, IA
Click here to add this to my saved trials
FES-PET for Patients Treated on NCI Protocol 8762
Positron Emission Tomography (PET) With 18F-Fluoroestradiol (FES) as a Predictor of Response in Patients With Breast Cancer Scheduled to be Treated With MK-2206 in Combination With Either an Aromatase Inhibitor or Fulvestrant on NCI Protocol 8762
Status: Enrolling
Updated:  10/24/2012
Mallinckrodt Institute of Radiology
mi
from
St. Louis, MO
FES-PET for Patients Treated on NCI Protocol 8762
Positron Emission Tomography (PET) With 18F-Fluoroestradiol (FES) as a Predictor of Response in Patients With Breast Cancer Scheduled to be Treated With MK-2206 in Combination With Either an Aromatase Inhibitor or Fulvestrant on NCI Protocol 8762
Status: Enrolling
Updated: 10/24/2012
Mallinckrodt Institute of Radiology
mi
from
St. Louis, MO
Click here to add this to my saved trials
Promotora-based Latino Family CVD Risk Reduction
Promotora-based Latino Family CVD Risk Reduction: Remaking the Home Environment
Status: Enrolling
Updated:  10/24/2012
Roybal Comprehensive Health Center
mi
from
Los Angeles, CA
Promotora-based Latino Family CVD Risk Reduction
Promotora-based Latino Family CVD Risk Reduction: Remaking the Home Environment
Status: Enrolling
Updated: 10/24/2012
Roybal Comprehensive Health Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated:  10/25/2012
Arkansas Children's Hospital
mi
from
Little Rock, AR
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated: 10/25/2012
Arkansas Children's Hospital
mi
from
Little Rock, AR
Click here to add this to my saved trials
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated:  10/25/2012
City of Hope National Medical Center
mi
from
Duarte, CA
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated: 10/25/2012
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated:  10/25/2012
The Children's Hospital
mi
from
Denver, CO
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated: 10/25/2012
The Children's Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated:  10/25/2012
A. I. duPont Hospital for Children
mi
from
Wilmington, DE
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated: 10/25/2012
A. I. duPont Hospital for Children
mi
from
Wilmington, DE
Click here to add this to my saved trials
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated:  10/25/2012
Nemours Children's Clinic
mi
from
Jacksonville, FL
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated: 10/25/2012
Nemours Children's Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated:  10/25/2012
Nemours Children's Clinic - Orlando
mi
from
Orlando, FL
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated: 10/25/2012
Nemours Children's Clinic - Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated:  10/25/2012
Backus Children's Hospital at University Pediatrics
mi
from
Savannah, GA
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated: 10/25/2012
Backus Children's Hospital at University Pediatrics
mi
from
Savannah, GA
Click here to add this to my saved trials
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated:  10/25/2012
University of Kentucky Chandler Medical Center
mi
from
Lexington, KY
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Different Doses of Palonosetron Compared to Ondansetron in the Prevention of CINV in Pediatric Patients Undergoing Single and Repeated Cycles of MEC or HEC
Status: Enrolling
Updated: 10/25/2012
University of Kentucky Chandler Medical Center
mi
from
Lexington, KY
Click here to add this to my saved trials